EBS · Emergent BioSolutions Inc.
$7.63
-0.06 (-0.78%)
At close · Jul 17
Market Cap
$393.68M
Shares
51.60M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joseph Papa | CEO | $5,321,147 |
| Richard S. Lindahl | CFO | $2,708,723 |
| Coleen Glessner | Executive Vice President, Quality and Ethics and Compliance | $1,664,258 |
| Simon Lowry | Chief Medical Officer, Head of Research and Development | $1,471,276 |
| Paul Williams | Senior Vice President and Head of Products | $1,391,158 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joseph Papa | CEO | $5,862,562 |
| Richard S. Lindahl | CFO | $2,311,320 |
| Coleen Glessner | Executive Vice President, Quality and Ethics and Compliance | $2,053,213 |
| William Hartzel | Senior Vice President, Manufacturing and Bioservices | $1,714,261 |
| Paul Williams | Senior Vice President and Head of Products | $1,675,687 |
| Jennifer Fox | General Counsel | $1,189,933 |
| Haywood Miller | CEO | $218,750 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert Kramer | CEO | $5,103,858 |
| Richard S. Lindahl | CFO | $2,178,980 |
| Jennifer Fox | General Counsel | $2,131,320 |
| Adam Havey | COO | $2,010,487 |
| Coleen Glessner | Executive Vice President, Quality and Ethics and Compliance | $1,681,538 |
| Paul Williams | Senior Vice President and Head of Products | $1,063,639 |
| Haywood Miller | CEO | $766,667 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert Kramer | CEO | $7,578,573 |
| Adam Havey | COO | $3,621,626 |
| Richard S. Lindahl | CFO | $3,522,762 |
| Atul Saran | General Counsel | $3,504,868 |
| Jennifer Fox | General Counsel | $2,923,207 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert Kramer | CEO | $6,932,076 |
| Fuad El-Hibri | Chairman | $3,515,977 |
| Richard S. Lindahl | CFO | $2,197,585 |
| Adam Havey | COO | $2,092,783 |
| Atul Saran | General Counsel | $2,070,344 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Kramer | CEO | $5,569,978 |
| Fuad El-Hibri | Chairman | $3,213,484 |
| Richard S. Lindahl | CFO | $2,281,300 |
| Adam Havey | COO | $2,175,528 |
| Atul Saran | General Counsel | $2,159,032 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Robert Kramer | CEO | $3,693,821 |
| Fuad El-Hibri | Chairman | $3,010,062 |
| Richard S. Lindahl | CFO | $1,877,497 |
| Atul Saran | General Counsel | $1,862,979 |
| Adam Havey | COO | $1,845,367 |
| Daniel J. Abdun-Nabi | CEO | $633,322 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Daniel J. Abdun-Nabi | CEO | $4,100,936 |
| Fuad El-Hibri | Chairman | $2,970,218 |
| Robert Kramer | CEO | $2,396,747 |
| Atul Saran | General Counsel | $1,698,027 |
| Corporate Development | General Counsel | $1,698,027 |
| Adam Havey | EVP of Business Operations | $1,659,081 |
| Richard S. Lindahl | CFO | $1,612,453 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Daniel J. Abdun-Nabi | CEO | $3,681,284 |
| Fuad El-Hibri | Chairman | $2,567,482 |
| Robert Kramer | CEO | $1,712,371 |
| Corporate Development | General Counsel | $1,220,554 |
| Adam Havey | EVP of Business Operations | $1,158,295 |
Key facts
CIK
1367644
CUSIP
29089Q105
13F (30d)
15 filings
15 filers
Visit website
Investor relations